Paragon Health Institute Icon White

Brian Blase quoted in The Wall Street Journal story “Medicaid Proposed Rule Aims to Ease the Enrollment Process”

Shutterstock 118615129 10
President at Paragon Health Institute
Brian Blase, Ph.D., is the President of Paragon Health Institute. Brian was Special Assistant to the President for Economic Policy at the White House’s National Economic Council (NEC) from 2017-2019, where he coordinated the development and execution of numerous health policies and advised the President, NEC director, and senior officials. After leaving the White House, Brian founded Blase Policy Strategies and serves as its CEO.

Stephanie Armour

Print Friendly, PDF & Email

On August 31st, 2022, Paragon President Brian Blase was quoted in The Wall Street Journal for their story “Medicaid Proposed Rule Aims to Ease the Enrollment Process.”

The story says:

The Biden administration on Wednesday proposed a rule to overhaul Medicaid’s enrollment processes, aimed at establishing more consistency across state programs, while making it easier for beneficiaries to get and retain health coverage.

The changes would standardize Medicaid’s eligibility and enrollment policies, and include limiting the requirement that individuals’ renew benefit eligibility to once every 12 months. The renewal process isn’t currently uniform across all states.

Brian was quoted in the story to explain that this proposed rule challenges to overall viability of Medicaid.

“The biggest problem: a huge number of people enrolled in Medicaid are not eligible, depriving resources from the truly needy,” said Brian Blase, president of Paragon Health Institute, which analyzes government health programs and policies. Mr. Blase helped direct former President Donald Trump’s health policy agenda. Mr. Blase has said many beneficiaries are ineligible because they earn too much, and some also aren’t lawfully present in the U.S.

“The Biden administration should focus on reducing the massive waste, fraud, abuse, and misspending in Medicaid, and limiting eligibility reviews is counterproductive to that goal,” he said.

The full article can be found in The Wall Street Journal.

Related Content

Subscribe

Sign up now for your health policy updates.

Name(Required)
This field is for validation purposes and should be left unchanged.